Glendon E. French III sold $14k of LUNG
President and CEO at Pulmonx Corp. 8,805 shares at an average of $1.57, traded Dec 1, 2025, filed Dec 3, 2025.
Score components
- +25RoleCEO
- 0Trade size$14k at market
- 0Share of holdings soldSold 3.1% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +21.7%, 3m -23.8%, 6m -19.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001805624-25-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2025 | SOpen-market sale Common Stock | -2,524 | $1.57 | $3,963 | 283,605 | Dec 3, 2025 |
| Dec 1, 2025 | SOpen-market sale Common Stock | -6,281 | $1.57 | $9,861 | 277,324 | Dec 3, 2025 |
| Dec 1, 2025 | AGrant or award Common Stock | +1,200,000 | $0.00 | $0 | 1,477,324 | Dec 3, 2025 |
| Dec 1, 2025 | AGrant or award Performance Stock Unitsderivative | +800,000 | $0.00 | $0 | 800,000 | Dec 3, 2025 |
Related signals
Other insiders at Pulmonx Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Pulmonx Corp | Glendon E. French III President and CEO | $95k 41,882 shares | -4% | |
| 35Weak | Pulmonx Corp | David Aaron Lehman General Counsel | $32k 14,334 shares | -4% | |
| 30Weak | Pulmonx Corp | Geoffrey Beran Rose Chief Commercial Officer | $18k 7,879 shares | -2% | |
| 35Weak | Pulmonx Corp | Srikanth Radhakrishnan Chief Science & Techn. Officer | $32k 14,245 shares | -4% | |
| 49Moderate | Pulmonx Corp | Glendon E. French III President and CEO | $87k 56,149 shares | -5% | |
| 30Weak | Pulmonx Corp | David Aaron Lehman GENERAL COUNSEL | $22k 14,594 shares | -4% | |
| 30Weak | Pulmonx Corp | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | $12k 8,023 shares | -2% | |
| 30Weak | Pulmonx Corp | Srikanth Radhakrishnan Chief Science &Techn. Officer | $22k 14,497 shares | -4% | |
| 50Moderate | Pulmonx Corp | Glendon E. French III President and CEO | $97k 67,813 shares | -5% | |
| 30Weak | Pulmonx Corp | David Aaron Lehman GENERAL COUNSEL | $17k 12,237 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.